id
stringlengths 9
9
| image
imagewidth (px) 2.04k
2.04k
| question
stringlengths 196
315
| answer
stringlengths 1.04k
1.54k
|
|---|---|---|---|
case_0001
|
Planning for pre-surgical bone mapping. Brief history/status: Amlodipine, Calcichew-D3, Bufomix Easyhaler, Betolvex, Losartan, Levaxin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 36–46.
|
Review of CBCT volume dated 210506. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 15: bone height ≈ 17.4 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 20.5 mm; implant space ≈ 14.0 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 6.4 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 16.7 mm; implant space ≈ 14.2 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 9.6 mm; implant space ≈ 1.8 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 9.2 mm; implant space ≈ 4.3 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 15.1 mm; implant space ≈ 8.7 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 13.4 mm; implant space ≈ 11.7 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 15.0 mm; implant space ≈ 11.6 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 44, likely radicular cyst.
|
|
case_0002
|
Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Bricanyl, Metoprolol, Losartan, Bufomix Easyhaler, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.
|
Review of CBCT volume dated 221114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 16.9 mm; implant space ≈ 13.9 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 7.1 mm; implant space ≈ 3.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 12.9 mm; implant space ≈ 9.1 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 16.3 mm; implant space ≈ 10.4 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 15.8 mm; implant space ≈ 10.8 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 14.6 mm; implant space ≈ 9.5 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 5.5 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 12.0 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.6 mm; implant space ≈ 2.4 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0003
|
Planning for assessment for guided surgery. Brief history/status: Esomeprazole, Duroferon, Amlodipine, Trulicity, Calcichew-D3, Bricanyl, Duloxetine, Atorvastatin. Desired treatment: Quantify vertical bone loss around implants in 17–27 and assess anterior maxillary density.
|
Review of CBCT volume dated 210511. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 9.7 mm; implant space ≈ 1.4 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 9.9 mm; implant space ≈ 5.1 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 11.9 mm; implant space ≈ 7.6 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 16.1 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 9.7 mm; implant space ≈ 6.5 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 21.3 mm; implant space ≈ 17.5 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 6.4 mm; implant space ≈ 1.9 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 11.7 mm; implant space ≈ 8.1 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 17.1 mm; implant space ≈ 11.4 mm; nearest critical structure: mandibular canal. Periapical radiolucency present near 36; lamina dura loss noted. Secondary small radiolucency adjacent to 41. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0004
|
Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Esomeprazole, Calcichew-D3, Bricanyl, Metoprolol, Trulicity, Losartan, Levaxin, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.
|
Review of CBCT volume dated 241018. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.5 mm; implant space ≈ 14.2 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 15.5 mm; implant space ≈ 9.1 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 20.5 mm; implant space ≈ 16.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 13.1 mm; implant space ≈ 9.6 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 18.4 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 5.7 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 9.1 mm; implant space ≈ 5.0 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 20.9 mm; implant space ≈ 14.3 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 10.3 mm; implant space ≈ 6.4 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 7.9 mm; implant space ≈ 3.2 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 22, likely radicular cyst.
|
|
case_0005
|
Planning for implant planning evaluation. Brief history/status: Bricanyl, Betolvex, Bufomix Easyhaler, Metoprolol, Calcichew-D3, Insulin glargine. Desired treatment: Evaluate periapical status of teeth 16, 33, and 17, and overall sinus condition.
|
Review of CBCT volume dated 220221. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 19.0 mm; implant space ≈ 14.5 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 7.1 mm; implant space ≈ 1.4 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 10.8 mm; implant space ≈ 3.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 8.9 mm; implant space ≈ 0.4 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 20.4 mm; implant space ≈ 18.4 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 11.7 mm; implant space ≈ 5.3 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 20.8 mm; implant space ≈ 18.0 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 14.5 mm; implant space ≈ 7.4 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 11.1 mm; implant space ≈ 2.7 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 19.8 mm; implant space ≈ 15.2 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 46; recommend clinical correlation.
|
|
case_0006
|
Planning for delayed healing post endodontic therapy. Brief history/status: Calcichew-D3, Duloxetine, Bricanyl, Bufomix Easyhaler, Insulin glargine, Esomeprazole, Duroferon. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.
|
Review of CBCT volume dated 200716. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 28: bone height ≈ 14.5 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 10.3 mm; implant space ≈ 4.4 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 10.1 mm; implant space ≈ 1.8 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 5.6 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 8.5 mm; implant space ≈ 5.2 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 12.4 mm; implant space ≈ 8.5 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 9.7 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 16.2 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Impression: Findings consistent with chronic apical periodontitis at 38 and 25.
|
|
case_0007
|
Planning for pre-orthodontic assessment. Brief history/status: Bufomix Easyhaler, Duloxetine, Metoprolol, Bricanyl, Calcichew-D3, Trulicity, Esomeprazole, Betolvex, Losartan. Desired treatment: Quantify vertical bone loss around implants in 17–27 and assess anterior maxillary density.
|
Review of CBCT volume dated 221107. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.8 mm; implant space ≈ 13.9 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 10.6 mm; implant space ≈ 3.4 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 17.2 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 11.9 mm; implant space ≈ 4.8 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 21.7 mm; implant space ≈ 13.1 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 9.4 mm; implant space ≈ 6.8 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 7.0 mm; implant space ≈ 4.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 14.3 mm; implant space ≈ 7.1 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 4.1 mm; implant space ≈ 2.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 21.8 mm; implant space ≈ 17.9 mm; nearest critical structure: sinus floor. Periapical radiolucency present near 23; lamina dura loss noted. Secondary small radiolucency adjacent to 11. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0008
|
Planning for sinus-related complaints. Brief history/status: Esomeprazole, Betolvex, Calcichew-D3, Bufomix Easyhaler, Bricanyl, Amlodipine, Losartan, Duroferon, Atorvastatin. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.
|
Review of CBCT volume dated 210215. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 14.3 mm; implant space ≈ 6.8 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 17.2 mm; implant space ≈ 12.2 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 9.6 mm; implant space ≈ 5.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 9.6 mm; implant space ≈ 0.8 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 11.6 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 10.3 mm; implant space ≈ 4.4 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 19.7 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 19.0 mm; implant space ≈ 15.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 16.9 mm; implant space ≈ 15.3 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 21.7 mm; implant space ≈ 17.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0009
|
Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Amlodipine, Levaxin, Metoprolol, Esomeprazole, Calcichew-D3, Insulin glargine. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 17–27.
|
Review of CBCT volume dated 201028. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 12: bone height ≈ 20.0 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 9.4 mm; implant space ≈ 6.9 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 12.1 mm; implant space ≈ 3.8 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 18.3 mm; implant space ≈ 9.9 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 7.0 mm; implant space ≈ 1.6 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 19.4 mm; implant space ≈ 16.8 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 12.7 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 45: bone height ≈ 11.6 mm; implant space ≈ 7.3 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0010
|
Planning for sinus-related complaints. Brief history/status: Duloxetine, Losartan, Bufomix Easyhaler, Amlodipine, Atorvastatin, Betolvex, Metoprolol, Trulicity. Desired treatment: Evaluate periapical status of teeth 41, 12, and 44, and overall sinus condition.
|
Review of CBCT volume dated 251105. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 14: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 14.3 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 4.6 mm; implant space ≈ 1.4 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 16.8 mm; implant space ≈ 14.5 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 16.6 mm; implant space ≈ 13.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 21.0 mm; implant space ≈ 12.4 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 5.7 mm; implant space ≈ 0.8 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 8.1 mm; implant space ≈ 6.1 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 23; lamina dura loss noted. Secondary small radiolucency adjacent to 44. Impression: Peri-implant bone loss at 23 within the coronal third, suggestive of peri-implantitis.
|
|
case_0011
|
Planning for implant site evaluation. Brief history/status: Amlodipine, Losartan, Esomeprazole, Levaxin, Metoprolol, Betolvex. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.
|
Review of CBCT volume dated 230306. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 8.5 mm; implant space ≈ 3.5 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 15.6 mm; implant space ≈ 11.9 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 15.7 mm; implant space ≈ 6.8 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 14.1 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 21.1 mm; implant space ≈ 13.9 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 8.0 mm; implant space ≈ 0.6 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 19.9 mm; implant space ≈ 14.8 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 20.6 mm; implant space ≈ 13.6 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 8.1 mm; implant space ≈ 1.2 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 10.9 mm; implant space ≈ 6.7 mm; nearest critical structure: nasal floor. Impression: Peri-implant bone loss at 31 within the coronal third, suggestive of peri-implantitis.
|
|
case_0012
|
Planning for pre-surgical bone mapping. Brief history/status: Calcichew-D3, Metoprolol, Duloxetine, Levaxin, Trulicity, Esomeprazole, Amlodipine, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.
|
Review of CBCT volume dated 220513. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 36: bone height ≈ 8.7 mm; implant space ≈ 1.5 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 20.2 mm; implant space ≈ 17.4 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 9.2 mm; implant space ≈ 5.6 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 20.9 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 7.6 mm; implant space ≈ 4.4 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 7.1 mm; implant space ≈ 4.3 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 21.2 mm; implant space ≈ 14.2 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 16.4 mm; implant space ≈ 12.2 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 23 and 18.
|
|
case_0013
|
Planning for full-arch restoration. Brief history/status: Bricanyl, Atorvastatin, Losartan, Amlodipine, Duloxetine, Duroferon, Esomeprazole, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.
|
Review of CBCT volume dated 240608. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 33: bone height ≈ 15.7 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 4.3 mm; implant space ≈ 2.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 8.5 mm; implant space ≈ 1.1 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 10.4 mm; implant space ≈ 8.5 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 22.0 mm; implant space ≈ 18.0 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 14.7 mm; implant space ≈ 9.6 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 12.0 mm; implant space ≈ 10.0 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 10.5 mm; implant space ≈ 3.4 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 14.7 mm; implant space ≈ 6.2 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 37; lamina dura loss noted. Secondary small radiolucency adjacent to 26. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0014
|
Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Metoprolol, Duroferon, Amlodipine, Betolvex, Duloxetine, Insulin glargine, Bricanyl, Bufomix Easyhaler. Desired treatment: Please report bone height and available implant space for regions 37–47 and 35–45.
|
Review of CBCT volume dated 220209. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 31: bone height ≈ 14.4 mm; implant space ≈ 11.2 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 16.2 mm; implant space ≈ 9.7 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 16.6 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 20.4 mm; implant space ≈ 13.0 mm; nearest critical structure: sinus floor. Region 33: bone height ≈ 13.2 mm; implant space ≈ 10.1 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 14.1 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 14.3 mm; implant space ≈ 8.1 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 16.1 mm; implant space ≈ 14.3 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 10.4 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 12.4 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 24; lamina dura loss noted. Secondary small radiolucency adjacent to 14. Impression: Vertical root fracture suspected at 14; recommend clinical correlation.
|
|
case_0015
|
Planning for implant site evaluation. Brief history/status: Bricanyl, Duroferon, Trulicity, Calcichew-D3, Metoprolol, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.
|
Review of CBCT volume dated 210705. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 46: bone height ≈ 7.8 mm; implant space ≈ 3.4 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 10.1 mm; implant space ≈ 3.2 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 14.6 mm; implant space ≈ 9.1 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 4.3 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 7.3 mm; implant space ≈ 3.6 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 17.6 mm; implant space ≈ 15.9 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 7.9 mm; implant space ≈ 2.3 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 20.3 mm; implant space ≈ 17.8 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 20.3 mm; implant space ≈ 12.6 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 21.2 mm; implant space ≈ 17.2 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 38; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0016
|
Planning for sinus-related complaints. Brief history/status: Insulin glargine, Metoprolol, Levaxin, Esomeprazole, Atorvastatin. Desired treatment: Evaluate periapical status of teeth 16, 46, and 22, and overall sinus condition.
|
Review of CBCT volume dated 251001. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 17.4 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 13.0 mm; implant space ≈ 9.5 mm; nearest critical structure: incisive canal. Region 21: bone height ≈ 7.9 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 9.3 mm; implant space ≈ 2.1 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 6.2 mm; implant space ≈ 0.4 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 14.8 mm; implant space ≈ 10.1 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 17.1 mm; implant space ≈ 13.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 6.5 mm; implant space ≈ 4.9 mm; nearest critical structure: incisive canal. Region 42: bone height ≈ 21.1 mm; implant space ≈ 13.4 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 9.6 mm; implant space ≈ 4.9 mm; nearest critical structure: mandibular canal. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0017
|
Planning for implant planning evaluation. Brief history/status: Calcichew-D3, Trulicity, Esomeprazole, Metoprolol, Insulin glargine, Levaxin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 16–26.
|
Review of CBCT volume dated 240404. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 5.4 mm; implant space ≈ 0.7 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 7.7 mm; implant space ≈ 0.2 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 10.5 mm; implant space ≈ 5.4 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 17.2 mm; implant space ≈ 9.2 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 18.6 mm; implant space ≈ 10.2 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 16.0 mm; implant space ≈ 8.4 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 12.3 mm; implant space ≈ 3.5 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 20.5 mm; implant space ≈ 17.5 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 8.3 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 11.1 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Periapical radiolucency present near 22; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination.
|
|
case_0018
|
Planning for assessment for guided surgery. Brief history/status: Atorvastatin, Duloxetine, Losartan, Duroferon, Bufomix Easyhaler, Esomeprazole, Insulin glargine, Calcichew-D3. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 17–27.
|
Review of CBCT volume dated 251008. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 14: bone height ≈ 8.4 mm; implant space ≈ 4.7 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 18.8 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 14.6 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 19.2 mm; implant space ≈ 15.2 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 21.5 mm; implant space ≈ 15.9 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 11.8 mm; implant space ≈ 4.2 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 13.2 mm; implant space ≈ 5.8 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 7.5 mm; implant space ≈ 2.5 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Periapical radiolucency present near 41; lamina dura loss noted. Secondary small radiolucency adjacent to 46. Impression: Vertical root fracture suspected at 25; recommend clinical correlation.
|
|
case_0019
|
Planning for full-arch restoration. Brief history/status: Calcichew-D3, Amlodipine, Levaxin, Losartan, Bufomix Easyhaler, Trulicity, Insulin glargine. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.
|
Review of CBCT volume dated 210302. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 11: bone height ≈ 9.3 mm; implant space ≈ 2.4 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 16.6 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 21.0 mm; implant space ≈ 14.7 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 11.5 mm; implant space ≈ 10.0 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 11.2 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 17.7 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 21.3 mm; implant space ≈ 13.5 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 11.8 mm; implant space ≈ 6.0 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 15.6 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 9.9 mm; implant space ≈ 7.8 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 42; lamina dura loss noted. Secondary small radiolucency adjacent to 47. Impression: Findings consistent with chronic apical periodontitis at 33 and 31.
|
|
case_0020
|
Planning for sinus-related complaints. Brief history/status: Duroferon, Duloxetine, Losartan, Bufomix Easyhaler, Betolvex, Amlodipine, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 17–27 and 16–26.
|
Review of CBCT volume dated 250911. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 47: bone height ≈ 15.8 mm; implant space ≈ 13.4 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 17.0 mm; implant space ≈ 12.2 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 6.8 mm; implant space ≈ 2.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 9.7 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 15.0 mm; implant space ≈ 12.3 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 12.4 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 21.4 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 17.1 mm; implant space ≈ 11.7 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 16.0 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 5.8 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0021
|
Planning for assessment for guided surgery. Brief history/status: Esomeprazole, Metoprolol, Calcichew-D3, Trulicity, Duloxetine, Betolvex. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.
|
Review of CBCT volume dated 230725. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 36: bone height ≈ 10.2 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 5.5 mm; implant space ≈ 0.7 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 13.4 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 14.4 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 18.0 mm; implant space ≈ 13.9 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 18.7 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 10.5 mm; implant space ≈ 8.0 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 19.2 mm; implant space ≈ 15.0 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 6.9 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 15.7 mm; implant space ≈ 9.1 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0022
|
Planning for persistent pain on mastication. Brief history/status: Losartan, Bufomix Easyhaler, Betolvex, Insulin glargine, Trulicity, Duloxetine, Calcichew-D3, Amlodipine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.
|
Review of CBCT volume dated 230722. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 13: bone height ≈ 21.9 mm; implant space ≈ 15.1 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 16.5 mm; implant space ≈ 13.4 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 17.3 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 21.0 mm; implant space ≈ 17.0 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 14.6 mm; implant space ≈ 12.3 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 14.5 mm; implant space ≈ 6.6 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 7.5 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 15: bone height ≈ 14.8 mm; implant space ≈ 11.4 mm; nearest critical structure: nasal floor. Periapical radiolucency present near 24; lamina dura loss noted. Secondary small radiolucency adjacent to 44. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0023
|
Planning for pre-surgical bone mapping. Brief history/status: Amlodipine, Calcichew-D3, Levaxin, Bufomix Easyhaler, Bricanyl. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.
|
Review of CBCT volume dated 230408. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 11: bone height ≈ 11.0 mm; implant space ≈ 5.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.5 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 19.9 mm; implant space ≈ 12.3 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 5.9 mm; implant space ≈ 3.2 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 19.6 mm; implant space ≈ 16.7 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 10.6 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 18.4 mm; implant space ≈ 13.8 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 15.7 mm; implant space ≈ 11.8 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 12.1 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 11.6 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 27; lamina dura loss noted. Secondary small radiolucency adjacent to 33. Impression: Cyst-like well-defined radiolucency near 37, likely radicular cyst.
|
|
case_0024
|
Planning for implant planning evaluation. Brief history/status: Trulicity, Calcichew-D3, Duroferon, Levaxin, Insulin glargine, Losartan, Atorvastatin, Bufomix Easyhaler, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 16–26.
|
Review of CBCT volume dated 201023. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 23: bone height ≈ 13.7 mm; implant space ≈ 8.2 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 7.2 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 20.4 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 16.1 mm; implant space ≈ 9.3 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 11.5 mm; implant space ≈ 3.9 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 20.0 mm; implant space ≈ 18.5 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 14.5 mm; implant space ≈ 8.0 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.6 mm; implant space ≈ 8.3 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 9.1 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 31 and 32.
|
|
case_0025
|
Planning for pre-surgical bone mapping. Brief history/status: Levaxin, Bricanyl, Amlodipine, Bufomix Easyhaler, Duroferon, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.
|
Review of CBCT volume dated 251102. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 35: bone height ≈ 7.1 mm; implant space ≈ 2.0 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 21.9 mm; implant space ≈ 14.6 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 10.3 mm; implant space ≈ 7.1 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 21.6 mm; implant space ≈ 15.7 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 10.8 mm; implant space ≈ 1.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 14.8 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 8.3 mm; implant space ≈ 3.0 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 11.7 mm; implant space ≈ 9.9 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 17.4 mm; implant space ≈ 15.4 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 9.1 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 16, likely radicular cyst.
|
|
case_0026
|
Planning for persistent pain on mastication. Brief history/status: Trulicity, Bricanyl, Levaxin, Amlodipine, Atorvastatin, Duroferon, Esomeprazole, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 16–26 and 17–27.
|
Review of CBCT volume dated 250920. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.9 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 15.3 mm; implant space ≈ 12.5 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 18.4 mm; implant space ≈ 12.7 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 13.7 mm; implant space ≈ 5.4 mm; nearest critical structure: incisive canal. Region 28: bone height ≈ 14.5 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 18.5 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 17.4 mm; implant space ≈ 11.2 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 7.8 mm; implant space ≈ 5.8 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 6.0 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 17.4 mm; implant space ≈ 9.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 21; lamina dura loss noted. Secondary small radiolucency adjacent to 48. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0027
|
Planning for implant site evaluation. Brief history/status: Metoprolol, Esomeprazole, Atorvastatin, Bufomix Easyhaler, Betolvex, Calcichew-D3, Duloxetine, Levaxin, Duroferon. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.
|
Review of CBCT volume dated 241210. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 36: bone height ≈ 5.1 mm; implant space ≈ 3.4 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 7.5 mm; implant space ≈ 5.2 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 15.7 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 4.7 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 5.9 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 13.6 mm; implant space ≈ 7.6 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 10.4 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 7.9 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 6.6 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 10.0 mm; implant space ≈ 3.8 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 4 with mesioangular inclination.
|
|
case_0028
|
Planning for sinus-related complaints. Brief history/status: Bufomix Easyhaler, Levaxin, Esomeprazole, Trulicity, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.
|
Review of CBCT volume dated 250125. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 10.6 mm; implant space ≈ 4.0 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 6.6 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 18.9 mm; implant space ≈ 17.1 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 19.0 mm; implant space ≈ 16.1 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 6.9 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 14.1 mm; implant space ≈ 11.7 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 7.5 mm; implant space ≈ 3.3 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 12.3 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 14.1 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 9.8 mm; implant space ≈ 4.3 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination.
|
|
case_0029
|
Planning for implant site evaluation. Brief history/status: Levaxin, Losartan, Duloxetine, Trulicity, Calcichew-D3, Insulin glargine, Bufomix Easyhaler, Esomeprazole, Amlodipine. Desired treatment: Measure crest-to-canal distances mandibularly in 36–46, and implant feasibility maxillary 35–45.
|
Review of CBCT volume dated 220702. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 9.1 mm; implant space ≈ 1.1 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 15.9 mm; implant space ≈ 13.7 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 16.9 mm; implant space ≈ 15.0 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 4.7 mm; implant space ≈ 1.7 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 14.2 mm; implant space ≈ 11.3 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 16.4 mm; implant space ≈ 8.1 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 14.2 mm; implant space ≈ 9.4 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 12.4 mm; implant space ≈ 4.8 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 16.7 mm; implant space ≈ 11.7 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0030
|
Planning for sinus-related complaints. Brief history/status: Betolvex, Insulin glargine, Duloxetine, Calcichew-D3, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.
|
Review of CBCT volume dated 200326. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 10.3 mm; implant space ≈ 1.3 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 12.6 mm; implant space ≈ 10.2 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 19.8 mm; implant space ≈ 12.8 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 18.8 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 9.3 mm; implant space ≈ 4.9 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 10.5 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 6.7 mm; implant space ≈ 2.5 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 14.3 mm; implant space ≈ 10.7 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 13.3 mm; implant space ≈ 8.0 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 9.1 mm; implant space ≈ 4.6 mm; nearest critical structure: mandibular canal. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0031
|
Planning for implant site evaluation. Brief history/status: Atorvastatin, Metoprolol, Amlodipine, Bricanyl, Bufomix Easyhaler, Insulin glargine. Desired treatment: Please report bone height and available implant space for regions 17–27 and 36–46.
|
Review of CBCT volume dated 240128. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 20.1 mm; implant space ≈ 17.9 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 14.3 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 9.0 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 15.9 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 6.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 16.6 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 17.1 mm; implant space ≈ 11.2 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 12.2 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 15.9 mm; implant space ≈ 11.9 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 33; lamina dura loss noted. Secondary small radiolucency adjacent to 27. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0032
|
Planning for pre-surgical bone mapping. Brief history/status: Duloxetine, Levaxin, Insulin glargine, Esomeprazole, Bufomix Easyhaler. Desired treatment: Please report bone height and available implant space for regions 35–45 and 37–47.
|
Review of CBCT volume dated 231023. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 7.5 mm; implant space ≈ 5.7 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 9.4 mm; implant space ≈ 3.9 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 8.4 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 20.5 mm; implant space ≈ 13.1 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 18.0 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 12.4 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 15.0 mm; implant space ≈ 9.6 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 12.3 mm; implant space ≈ 8.9 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 4.9 mm; implant space ≈ 0.6 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 37; lamina dura loss noted. Secondary small radiolucency adjacent to 32. Impression: Findings consistent with chronic apical periodontitis at 25 and 36.
|
|
case_0033
|
Planning for persistent pain on mastication. Brief history/status: Betolvex, Atorvastatin, Esomeprazole, Bufomix Easyhaler, Trulicity, Calcichew-D3, Insulin glargine, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 16–26 and 36–46.
|
Review of CBCT volume dated 200210. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 10.9 mm; implant space ≈ 5.4 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 14.2 mm; implant space ≈ 10.5 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 16.4 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 22: bone height ≈ 20.1 mm; implant space ≈ 17.0 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 15.5 mm; implant space ≈ 7.7 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 19.6 mm; implant space ≈ 17.9 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 11.4 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 12.9 mm; implant space ≈ 7.2 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 16.0 mm; implant space ≈ 12.3 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 21.3 mm; implant space ≈ 19.6 mm; nearest critical structure: mandibular canal. Impression: Peri-implant bone loss at 26 within the coronal third, suggestive of peri-implantitis.
|
|
case_0034
|
Planning for implant site evaluation. Brief history/status: Metoprolol, Losartan, Insulin glargine, Calcichew-D3, Levaxin, Amlodipine, Betolvex, Esomeprazole. Desired treatment: Provide measurements relevant to guided surgery stent planning for 36–46 and 35–45.
|
Review of CBCT volume dated 250510. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 17.3 mm; implant space ≈ 11.2 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 15.7 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 4.5 mm; implant space ≈ 0.9 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 9.5 mm; implant space ≈ 2.2 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 16.9 mm; implant space ≈ 11.1 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 11.4 mm; implant space ≈ 2.7 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 19.3 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 14.5 mm; implant space ≈ 11.5 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 12.8 mm; implant space ≈ 5.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 21.1 mm; implant space ≈ 13.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0035
|
Planning for follow-up after extraction. Brief history/status: Trulicity, Duloxetine, Duroferon, Calcichew-D3, Levaxin. Desired treatment: Please report bone height and available implant space for regions 37–47 and 35–45.
|
Review of CBCT volume dated 210527. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 21.8 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 12.0 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 16.6 mm; implant space ≈ 8.9 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 16.5 mm; implant space ≈ 9.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 19.8 mm; implant space ≈ 13.4 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 7.5 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 5.7 mm; implant space ≈ 2.4 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 12.4 mm; implant space ≈ 5.6 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 14.8 mm; implant space ≈ 7.7 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Peri-implant bone loss at 31 within the coronal third, suggestive of peri-implantitis.
|
|
case_0036
|
Planning for persistent pain on mastication. Brief history/status: Losartan, Bufomix Easyhaler, Calcichew-D3, Metoprolol, Bricanyl, Atorvastatin, Duroferon, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.
|
Review of CBCT volume dated 220423. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 16.8 mm; implant space ≈ 9.7 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 13.4 mm; implant space ≈ 10.3 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 6.2 mm; implant space ≈ 2.5 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 11.3 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Region 11: bone height ≈ 15.6 mm; implant space ≈ 11.6 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 8.4 mm; implant space ≈ 2.7 mm; nearest critical structure: sinus floor. Region 48: bone height ≈ 7.8 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 18.2 mm; implant space ≈ 15.1 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 12.1 mm; implant space ≈ 10.1 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 15.2 mm; implant space ≈ 10.7 mm; nearest critical structure: sinus floor. Periapical radiolucency present near 26; lamina dura loss noted. Secondary small radiolucency adjacent to 22. Impression: Cyst-like well-defined radiolucency near 11, likely radicular cyst.
|
|
case_0037
|
Planning for follow-up after extraction. Brief history/status: Atorvastatin, Esomeprazole, Betolvex, Metoprolol, Duroferon, Bricanyl, Trulicity, Levaxin, Insulin glargine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 16–26.
|
Review of CBCT volume dated 211117. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 47: bone height ≈ 18.9 mm; implant space ≈ 12.2 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 13.7 mm; implant space ≈ 5.0 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 16.1 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 6.4 mm; implant space ≈ 0.1 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 20.9 mm; implant space ≈ 18.5 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 10.1 mm; implant space ≈ 4.5 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 4.2 mm; implant space ≈ 2.1 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 8.6 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 18.8 mm; implant space ≈ 12.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination.
|
|
case_0038
|
Planning for sinus-related complaints. Brief history/status: Metoprolol, Duroferon, Betolvex, Calcichew-D3, Bufomix Easyhaler, Esomeprazole, Amlodipine. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.
|
Review of CBCT volume dated 220224. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 31: bone height ≈ 7.0 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 14.6 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 21.7 mm; implant space ≈ 16.6 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 9.2 mm; implant space ≈ 5.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 9.5 mm; implant space ≈ 0.7 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 19.6 mm; implant space ≈ 15.6 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 11.8 mm; implant space ≈ 9.0 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 7.8 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 11.5 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0039
|
Planning for implant planning evaluation. Brief history/status: Duroferon, Levaxin, Losartan, Calcichew-D3, Atorvastatin, Amlodipine. Desired treatment: Please report bone height and available implant space for regions 17–27 and 15–25.
|
Review of CBCT volume dated 241019. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 21: bone height ≈ 17.0 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 17.6 mm; implant space ≈ 11.4 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 7.4 mm; implant space ≈ 3.0 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 12.5 mm; implant space ≈ 3.8 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 13.1 mm; implant space ≈ 5.5 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 9.5 mm; implant space ≈ 7.6 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 11.1 mm; implant space ≈ 6.5 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 8.9 mm; implant space ≈ 4.7 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 10.9 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination.
|
|
case_0040
|
Planning for pre-orthodontic assessment. Brief history/status: Metoprolol, Bufomix Easyhaler, Calcichew-D3, Losartan, Amlodipine, Bricanyl, Esomeprazole, Duroferon. Desired treatment: Please report bone height and available implant space for regions 15–25 and 35–45.
|
Review of CBCT volume dated 220723. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 19.2 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 7.6 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 10.1 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 17.8 mm; implant space ≈ 15.6 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 14.0 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 4.6 mm; implant space ≈ 1.2 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 8.1 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 16.2 mm; implant space ≈ 9.3 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 7.1 mm; implant space ≈ 1.2 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 10.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 45; lamina dura loss noted. Secondary small radiolucency adjacent to 15. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 22, likely radicular cyst.
|
|
case_0041
|
Planning for implant planning evaluation. Brief history/status: Calcichew-D3, Bufomix Easyhaler, Betolvex, Atorvastatin, Amlodipine, Losartan, Duloxetine. Desired treatment: Please report bone height and available implant space for regions 15–25 and 17–27.
|
Review of CBCT volume dated 240621. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.5 mm; implant space ≈ 8.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 9.6 mm; implant space ≈ 8.0 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 17.9 mm; implant space ≈ 10.0 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 11.0 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 15.7 mm; implant space ≈ 12.5 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 21.0 mm; implant space ≈ 13.5 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 16.9 mm; implant space ≈ 12.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 5.9 mm; implant space ≈ 0.4 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 24; lamina dura loss noted. Secondary small radiolucency adjacent to 26. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0042
|
Planning for full-arch restoration. Brief history/status: Losartan, Bricanyl, Duloxetine, Bufomix Easyhaler, Levaxin, Duroferon, Amlodipine, Betolvex, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 17–27 and 36–46.
|
Review of CBCT volume dated 250428. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 16: bone height ≈ 14.9 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 20.6 mm; implant space ≈ 12.7 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 14.2 mm; implant space ≈ 6.5 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 9.3 mm; implant space ≈ 4.6 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 12.9 mm; implant space ≈ 9.9 mm; nearest critical structure: incisive canal. Region 46: bone height ≈ 6.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 11.9 mm; implant space ≈ 5.6 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 11.3 mm; implant space ≈ 4.4 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 5.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 38 and 16.
|
|
case_0043
|
Planning for full-arch restoration. Brief history/status: Esomeprazole, Atorvastatin, Bufomix Easyhaler, Insulin glargine, Trulicity, Calcichew-D3. Desired treatment: Evaluate periapical status of teeth 37, 43, and 45, and overall sinus condition.
|
Review of CBCT volume dated 211007. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 23: bone height ≈ 11.4 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 25: bone height ≈ 18.7 mm; implant space ≈ 14.8 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 15.3 mm; implant space ≈ 8.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 18.1 mm; implant space ≈ 14.6 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 7.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 17.3 mm; implant space ≈ 14.3 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 5.3 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 15.3 mm; implant space ≈ 7.9 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 15.4 mm; implant space ≈ 7.6 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 17.1 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 28; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 22 and 15.
|
|
case_0044
|
Planning for pre-orthodontic assessment. Brief history/status: Duloxetine, Metoprolol, Atorvastatin, Amlodipine, Betolvex. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 15–25.
|
Review of CBCT volume dated 200813. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 42: bone height ≈ 14.0 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 10.1 mm; implant space ≈ 1.4 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 14.3 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 36: bone height ≈ 4.7 mm; implant space ≈ 2.5 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 5.1 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 20.4 mm; implant space ≈ 12.9 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 15.1 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 19.0 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 6.5 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 35 and 25.
|
|
case_0045
|
Planning for sinus-related complaints. Brief history/status: Duloxetine, Losartan, Duroferon, Metoprolol, Trulicity, Bufomix Easyhaler, Esomeprazole, Calcichew-D3, Betolvex. Desired treatment: Evaluate periapical status of teeth 33, 37, and 14, and overall sinus condition.
|
Review of CBCT volume dated 211121. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 9.3 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 21.4 mm; implant space ≈ 12.7 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 10.8 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 13.5 mm; implant space ≈ 11.9 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 8.3 mm; implant space ≈ 2.4 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 13.7 mm; implant space ≈ 5.2 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 5.8 mm; implant space ≈ 1.2 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 9.1 mm; implant space ≈ 3.3 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 18.4 mm; implant space ≈ 11.7 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 17; lamina dura loss noted. Secondary small radiolucency adjacent to 32. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Peri-implant bone loss at 25 within the coronal third, suggestive of peri-implantitis.
|
|
case_0046
|
Planning for follow-up after extraction. Brief history/status: Bricanyl, Duloxetine, Amlodipine, Bufomix Easyhaler, Duroferon, Levaxin, Calcichew-D3, Betolvex, Insulin glargine. Desired treatment: Quantify vertical bone loss around implants in 36–46 and assess anterior maxillary density.
|
Review of CBCT volume dated 231103. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 26: bone height ≈ 11.5 mm; implant space ≈ 3.7 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 17.9 mm; implant space ≈ 15.6 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 15.8 mm; implant space ≈ 10.3 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 19.2 mm; implant space ≈ 13.4 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 15.3 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 12.0 mm; implant space ≈ 4.1 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 7.3 mm; implant space ≈ 3.7 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 15.8 mm; implant space ≈ 10.4 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 11.8 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 38; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0047
|
Planning for implant planning evaluation. Brief history/status: Betolvex, Calcichew-D3, Duroferon, Bricanyl, Metoprolol, Losartan. Desired treatment: Evaluate periapical status of teeth 16, 26, and 18, and overall sinus condition.
|
Review of CBCT volume dated 220112. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 11.6 mm; implant space ≈ 3.7 mm; nearest critical structure: mandibular canal. Region 21: bone height ≈ 21.2 mm; implant space ≈ 16.5 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 19.1 mm; implant space ≈ 15.3 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 12.8 mm; implant space ≈ 7.7 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 11.6 mm; implant space ≈ 6.3 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 12.5 mm; implant space ≈ 6.1 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 18.9 mm; implant space ≈ 17.2 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 19.2 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 15.9 mm; implant space ≈ 12.9 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 37; lamina dura loss noted. Secondary small radiolucency adjacent to 28. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0048
|
Planning for implant planning evaluation. Brief history/status: Esomeprazole, Amlodipine, Duroferon, Bricanyl, Insulin glargine. Desired treatment: Report any signs of peri-implantitis and root resorption in 37–47.
|
Review of CBCT volume dated 230521. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 11.5 mm; implant space ≈ 5.1 mm; nearest critical structure: mental foramen. Region 27: bone height ≈ 14.8 mm; implant space ≈ 7.4 mm; nearest critical structure: sinus floor. Region 31: bone height ≈ 5.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 9.8 mm; implant space ≈ 4.3 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 19.9 mm; implant space ≈ 13.3 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 13.0 mm; implant space ≈ 5.0 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 14.7 mm; implant space ≈ 6.9 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 19.8 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 15.0 mm; implant space ≈ 6.3 mm; nearest critical structure: mental foramen. Region 41: bone height ≈ 6.8 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Periapical radiolucency present near 17; lamina dura loss noted. Secondary small radiolucency adjacent to 35. Impression: Findings consistent with chronic apical periodontitis at 18 and 38.
|
|
case_0049
|
Planning for assessment for guided surgery. Brief history/status: Atorvastatin, Losartan, Insulin glargine, Calcichew-D3, Amlodipine, Esomeprazole. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.
|
Review of CBCT volume dated 201218. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 46: bone height ≈ 7.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 6.3 mm; implant space ≈ 4.6 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 13.9 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 15.8 mm; implant space ≈ 10.2 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 17.2 mm; implant space ≈ 12.1 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 12.9 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 14.1 mm; implant space ≈ 8.8 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 14.7 mm; implant space ≈ 10.0 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 9.3 mm; implant space ≈ 1.0 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 9.3 mm; implant space ≈ 0.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 35, likely radicular cyst.
|
|
case_0050
|
Planning for implant site evaluation. Brief history/status: Losartan, Calcichew-D3, Duloxetine, Levaxin, Esomeprazole, Duroferon, Atorvastatin, Bricanyl. Desired treatment: Measure crest-to-canal distances mandibularly in 16–26, and implant feasibility maxillary 37–47.
|
Review of CBCT volume dated 250502. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 48: bone height ≈ 19.2 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 32: bone height ≈ 4.7 mm; implant space ≈ 1.7 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 12.1 mm; implant space ≈ 9.5 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 10.4 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 44: bone height ≈ 6.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 18.8 mm; implant space ≈ 16.0 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 10.4 mm; implant space ≈ 3.9 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 19.6 mm; implant space ≈ 13.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 13.6 mm; implant space ≈ 6.4 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 20.4 mm; implant space ≈ 11.9 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination.
|
|
case_0051
|
Planning for full-arch restoration. Brief history/status: Losartan, Levaxin, Calcichew-D3, Trulicity, Duroferon, Duloxetine, Bufomix Easyhaler, Bricanyl, Esomeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.
|
Review of CBCT volume dated 210918. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 19.5 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 15.6 mm; implant space ≈ 8.4 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 5.5 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 6.0 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 14.7 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 12.1 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 9.6 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 8.2 mm; implant space ≈ 1.5 mm; nearest critical structure: mental foramen. Region 32: bone height ≈ 7.3 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 8.8 mm; implant space ≈ 0.9 mm; nearest critical structure: anterior loop. Periapical radiolucency present near 36; lamina dura loss noted. Secondary small radiolucency adjacent to 37. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0052
|
Planning for sinus-related complaints. Brief history/status: Atorvastatin, Insulin glargine, Duroferon, Calcichew-D3, Betolvex, Levaxin, Amlodipine. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 17–27.
|
Review of CBCT volume dated 210612. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 12.1 mm; implant space ≈ 3.7 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 11.2 mm; implant space ≈ 3.6 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 6.1 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 9.3 mm; implant space ≈ 3.8 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 21.8 mm; implant space ≈ 14.5 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 6.1 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 9.1 mm; implant space ≈ 0.6 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 11.9 mm; implant space ≈ 6.4 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 12.3 mm; implant space ≈ 6.6 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 12.2 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Periapical radiolucency present near 45; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Cyst-like well-defined radiolucency near 13, likely radicular cyst.
|
|
case_0053
|
Planning for assessment for guided surgery. Brief history/status: Losartan, Calcichew-D3, Insulin glargine, Betolvex, Bricanyl, Metoprolol, Esomeprazole, Bufomix Easyhaler, Levaxin. Desired treatment: Quantify vertical bone loss around implants in 37–47 and assess anterior maxillary density.
|
Review of CBCT volume dated 250926. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 22: bone height ≈ 18.9 mm; implant space ≈ 16.2 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 20.3 mm; implant space ≈ 13.9 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 10.5 mm; implant space ≈ 5.4 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.0 mm; implant space ≈ 10.1 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 13.1 mm; implant space ≈ 6.0 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 16.3 mm; implant space ≈ 9.7 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.6 mm; implant space ≈ 1.4 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 6.6 mm; implant space ≈ 4.3 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 13.8 mm; implant space ≈ 9.1 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0054
|
Planning for persistent pain on mastication. Brief history/status: Amlodipine, Levaxin, Calcichew-D3, Duroferon, Betolvex, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.
|
Review of CBCT volume dated 210904. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 13.2 mm; implant space ≈ 7.1 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 13.3 mm; implant space ≈ 10.8 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 5.3 mm; implant space ≈ 1.5 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 7.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 17.3 mm; implant space ≈ 14.8 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 21.3 mm; implant space ≈ 13.7 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 8.3 mm; implant space ≈ 2.1 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 11.6 mm; implant space ≈ 6.1 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 9.3 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 22; lamina dura loss noted. Secondary small radiolucency adjacent to 32. Impression: Vertical root fracture suspected at 33; recommend clinical correlation.
|
|
case_0055
|
Planning for implant planning evaluation. Brief history/status: Bricanyl, Duloxetine, Bufomix Easyhaler, Trulicity, Esomeprazole, Metoprolol, Duroferon, Betolvex. Desired treatment: Measure crest-to-canal distances mandibularly in 37–47, and implant feasibility maxillary 16–26.
|
Review of CBCT volume dated 250216. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 14.4 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 5.4 mm; implant space ≈ 1.1 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 10.8 mm; implant space ≈ 3.7 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 4.1 mm; implant space ≈ 1.2 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 12.8 mm; implant space ≈ 9.1 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 4.5 mm; implant space ≈ 1.8 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 16.3 mm; implant space ≈ 14.3 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 9.8 mm; implant space ≈ 7.2 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 47; lamina dura loss noted. Secondary small radiolucency adjacent to 28. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0056
|
Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Insulin glargine, Duloxetine, Betolvex, Levaxin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 16–26.
|
Review of CBCT volume dated 240114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 31: bone height ≈ 21.2 mm; implant space ≈ 19.4 mm; nearest critical structure: anterior loop. Region 35: bone height ≈ 9.5 mm; implant space ≈ 7.1 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 10.7 mm; implant space ≈ 2.1 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 13.8 mm; implant space ≈ 8.3 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 21.8 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 11.9 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 21: bone height ≈ 15.4 mm; implant space ≈ 10.4 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 11.6 mm; implant space ≈ 7.5 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 12.1 mm; implant space ≈ 6.5 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 18.8 mm; implant space ≈ 9.8 mm; nearest critical structure: sinus floor. Periapical radiolucency present near 22; lamina dura loss noted. Secondary small radiolucency adjacent to 18. Streak artifacts from metallic restorations locally reduce interpretability. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0057
|
Planning for pre-orthodontic assessment. Brief history/status: Metoprolol, Levaxin, Calcichew-D3, Duroferon, Bufomix Easyhaler, Esomeprazole, Trulicity, Bricanyl, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 15–25 and 36–46.
|
Review of CBCT volume dated 200713. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 21.9 mm; implant space ≈ 15.4 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 4.8 mm; implant space ≈ 3.0 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 15.8 mm; implant space ≈ 12.6 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 18.1 mm; implant space ≈ 14.3 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 5.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 9.8 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 16.4 mm; implant space ≈ 8.3 mm; nearest critical structure: mandibular canal. Region 15: bone height ≈ 21.4 mm; implant space ≈ 18.9 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 4.7 mm; implant space ≈ 0.6 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 6.4 mm; implant space ≈ 0.3 mm; nearest critical structure: anterior loop. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination.
|
|
case_0058
|
Planning for pre-surgical bone mapping. Brief history/status: Insulin glargine, Losartan, Metoprolol, Betolvex, Trulicity, Amlodipine, Esomeprazole. Desired treatment: Report any signs of peri-implantitis and root resorption in 17–27.
|
Review of CBCT volume dated 240203. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 48: bone height ≈ 7.7 mm; implant space ≈ 3.4 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 19.3 mm; implant space ≈ 17.2 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 20.7 mm; implant space ≈ 18.5 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 18.4 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 20.7 mm; implant space ≈ 14.0 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 18.0 mm; implant space ≈ 11.6 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 18.6 mm; implant space ≈ 13.5 mm; nearest critical structure: nasal floor. Region 27: bone height ≈ 15.2 mm; implant space ≈ 6.4 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 8.8 mm; implant space ≈ 2.7 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0059
|
Planning for persistent pain on mastication. Brief history/status: Atorvastatin, Losartan, Betolvex, Calcichew-D3, Esomeprazole. Desired treatment: Please report bone height and available implant space for regions 17–27 and 35–45.
|
Review of CBCT volume dated 250223. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 38: bone height ≈ 13.6 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 15.6 mm; implant space ≈ 12.7 mm; nearest critical structure: mental foramen. Region 22: bone height ≈ 18.4 mm; implant space ≈ 16.6 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 14.6 mm; implant space ≈ 9.7 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 8.4 mm; implant space ≈ 2.4 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 13.8 mm; implant space ≈ 9.8 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 7.0 mm; implant space ≈ 2.8 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 7.2 mm; implant space ≈ 0.3 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 15.1 mm; implant space ≈ 12.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Vertical root fracture suspected at 24; recommend clinical correlation.
|
|
case_0060
|
Planning for pre-surgical bone mapping. Brief history/status: Duroferon, Duloxetine, Calcichew-D3, Bricanyl, Losartan, Metoprolol, Esomeprazole, Atorvastatin, Levaxin. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.
|
Review of CBCT volume dated 210425. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 15.4 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 25: bone height ≈ 9.6 mm; implant space ≈ 3.5 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 19.8 mm; implant space ≈ 11.4 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 13.1 mm; implant space ≈ 6.6 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 13.4 mm; implant space ≈ 10.9 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 12.4 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 8.6 mm; implant space ≈ 4.9 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 9.6 mm; implant space ≈ 3.2 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 21.8 mm; implant space ≈ 13.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 6.9 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 28 and 43.
|
|
case_0061
|
Planning for sinus-related complaints. Brief history/status: Amlodipine, Losartan, Trulicity, Insulin glargine, Atorvastatin, Betolvex, Levaxin, Metoprolol. Desired treatment: Measure crest-to-canal distances mandibularly in 17–27, and implant feasibility maxillary 37–47.
|
Review of CBCT volume dated 200217. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 25: bone height ≈ 6.3 mm; implant space ≈ 1.4 mm; nearest critical structure: nasal floor. Region 11: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 15.6 mm; implant space ≈ 13.1 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 8.2 mm; implant space ≈ 4.2 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 14.3 mm; implant space ≈ 9.1 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 21.9 mm; implant space ≈ 17.7 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 18.3 mm; implant space ≈ 10.2 mm; nearest critical structure: mandibular canal. Region 23: bone height ≈ 8.5 mm; implant space ≈ 4.7 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 16.7 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 44; lamina dura loss noted. Secondary small radiolucency adjacent to 33. Impression: Cyst-like well-defined radiolucency near 12, likely radicular cyst.
|
|
case_0062
|
Planning for follow-up after extraction. Brief history/status: Atorvastatin, Amlodipine, Betolvex, Insulin glargine, Duroferon, Levaxin, Metoprolol, Calcichew-D3, Trulicity. Desired treatment: Evaluate periapical status of teeth 38, 33, and 46, and overall sinus condition.
|
Review of CBCT volume dated 230328. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 18.8 mm; implant space ≈ 16.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 14.7 mm; implant space ≈ 12.8 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 15.4 mm; implant space ≈ 10.3 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 9.5 mm; implant space ≈ 7.4 mm; nearest critical structure: anterior loop. Region 28: bone height ≈ 9.1 mm; implant space ≈ 1.5 mm; nearest critical structure: incisive canal. Region 41: bone height ≈ 18.2 mm; implant space ≈ 15.7 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 12.0 mm; implant space ≈ 10.5 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 9.0 mm; implant space ≈ 4.1 mm; nearest critical structure: incisive canal. Region 32: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 14.8 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 32; lamina dura loss noted. Secondary small radiolucency adjacent to 46. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0063
|
Planning for persistent pain on mastication. Brief history/status: Amlodipine, Bricanyl, Atorvastatin, Insulin glargine, Duroferon. Desired treatment: Evaluate periapical status of teeth 15, 41, and 23, and overall sinus condition.
|
Review of CBCT volume dated 200525. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 23: bone height ≈ 21.3 mm; implant space ≈ 17.5 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 6.6 mm; implant space ≈ 1.1 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 8.7 mm; implant space ≈ 5.5 mm; nearest critical structure: mental foramen. Region 44: bone height ≈ 13.4 mm; implant space ≈ 6.4 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 17.4 mm; implant space ≈ 11.6 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 12.6 mm; implant space ≈ 9.0 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 12.2 mm; implant space ≈ 7.6 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 5.8 mm; implant space ≈ 3.8 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 19.0 mm; implant space ≈ 12.0 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 5.3 mm; implant space ≈ 1.8 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 28; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Impression: Peri-implant bone loss at 11 within the coronal third, suggestive of peri-implantitis.
|
|
case_0064
|
Planning for implant site evaluation. Brief history/status: Calcichew-D3, Duloxetine, Esomeprazole, Metoprolol, Bufomix Easyhaler, Bricanyl, Atorvastatin, Duroferon. Desired treatment: Evaluate periapical status of teeth 32, 15, and 47, and overall sinus condition.
|
Review of CBCT volume dated 230309. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 47: bone height ≈ 11.8 mm; implant space ≈ 5.6 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 5.8 mm; implant space ≈ 4.3 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 13.6 mm; implant space ≈ 5.2 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 11.5 mm; implant space ≈ 5.9 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 17.5 mm; implant space ≈ 13.9 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 19.6 mm; implant space ≈ 18.0 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 19.5 mm; implant space ≈ 16.7 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 19.0 mm; implant space ≈ 13.7 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 20.4 mm; implant space ≈ 18.8 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0065
|
Planning for implant planning evaluation. Brief history/status: Levaxin, Bufomix Easyhaler, Bricanyl, Losartan, Metoprolol, Trulicity. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.
|
Review of CBCT volume dated 250103. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 28: bone height ≈ 17.2 mm; implant space ≈ 11.2 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 19.4 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 31: bone height ≈ 15.0 mm; implant space ≈ 8.9 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 6.6 mm; implant space ≈ 2.7 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 14.7 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 10.5 mm; implant space ≈ 4.8 mm; nearest critical structure: sinus floor. Region 38: bone height ≈ 9.2 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Region 42: bone height ≈ 16.1 mm; implant space ≈ 9.6 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 20.5 mm; implant space ≈ 18.5 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 16; lamina dura loss noted. Secondary small radiolucency adjacent to 47. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Vertical root fracture suspected at 47; recommend clinical correlation.
|
|
case_0066
|
Planning for follow-up after extraction. Brief history/status: Esomeprazole, Metoprolol, Insulin glargine, Levaxin, Trulicity, Betolvex, Bricanyl. Desired treatment: Provide measurements relevant to guided surgery stent planning for 15–25 and 15–25.
|
Review of CBCT volume dated 211208. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 8.7 mm; implant space ≈ 4.7 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 6.5 mm; implant space ≈ 2.5 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 10.2 mm; implant space ≈ 6.9 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 20.6 mm; implant space ≈ 17.3 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 14.0 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Region 22: bone height ≈ 5.7 mm; implant space ≈ 3.5 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 5.6 mm; implant space ≈ 0.1 mm; nearest critical structure: anterior loop. Region 31: bone height ≈ 15.7 mm; implant space ≈ 9.5 mm; nearest critical structure: mental foramen. Region 11: bone height ≈ 18.3 mm; implant space ≈ 9.9 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 5.4 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 3 with mesioangular inclination.
|
|
case_0067
|
Planning for full-arch restoration. Brief history/status: Insulin glargine, Amlodipine, Duloxetine, Losartan, Duroferon, Metoprolol. Desired treatment: Please report bone height and available implant space for regions 36–46 and 15–25.
|
Review of CBCT volume dated 240828. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 46: bone height ≈ 11.9 mm; implant space ≈ 8.4 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 11.7 mm; implant space ≈ 7.8 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 15.1 mm; implant space ≈ 6.3 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 7.6 mm; implant space ≈ 1.2 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 6.7 mm; implant space ≈ 3.1 mm; nearest critical structure: anterior loop. Region 32: bone height ≈ 7.4 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 13.3 mm; implant space ≈ 7.0 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 18.2 mm; implant space ≈ 11.0 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 14.1 mm; implant space ≈ 6.4 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 15.7 mm; implant space ≈ 8.7 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 23; lamina dura loss noted. Secondary small radiolucency adjacent to 24. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0068
|
Planning for implant site evaluation. Brief history/status: Trulicity, Bricanyl, Insulin glargine, Duloxetine, Amlodipine. Desired treatment: Report any signs of peri-implantitis and root resorption in 35–45.
|
Review of CBCT volume dated 200503. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 11.9 mm; implant space ≈ 8.1 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 7.9 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 45: bone height ≈ 17.8 mm; implant space ≈ 10.1 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 6.8 mm; implant space ≈ 3.8 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 10.6 mm; implant space ≈ 8.0 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 6.6 mm; implant space ≈ 1.3 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 21.7 mm; implant space ≈ 19.4 mm; nearest critical structure: incisive canal. Region 13: bone height ≈ 9.7 mm; implant space ≈ 3.1 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 14.4 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 18.2 mm; implant space ≈ 15.2 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination.
|
|
case_0069
|
Planning for follow-up after extraction. Brief history/status: Insulin glargine, Trulicity, Bufomix Easyhaler, Esomeprazole, Duloxetine, Calcichew-D3, Amlodipine, Losartan, Bricanyl. Desired treatment: Evaluate periapical status of teeth 26, 22, and 48, and overall sinus condition.
|
Review of CBCT volume dated 240527. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 4.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 20.9 mm; implant space ≈ 16.3 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 13.8 mm; implant space ≈ 6.7 mm; nearest critical structure: incisive canal. Region 31: bone height ≈ 21.1 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 12: bone height ≈ 12.3 mm; implant space ≈ 9.6 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 15.0 mm; implant space ≈ 8.5 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 8.3 mm; implant space ≈ 1.2 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 4.5 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 20.6 mm; implant space ≈ 12.8 mm; nearest critical structure: incisive canal. Region 36: bone height ≈ 14.2 mm; implant space ≈ 7.4 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Findings consistent with chronic apical periodontitis at 24 and 11.
|
|
case_0070
|
Planning for full-arch restoration. Brief history/status: Metoprolol, Bricanyl, Levaxin, Trulicity, Losartan, Duroferon, Duloxetine. Desired treatment: Please report bone height and available implant space for regions 36–46 and 35–45.
|
Review of CBCT volume dated 200119. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 17: bone height ≈ 19.0 mm; implant space ≈ 17.5 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 11.8 mm; implant space ≈ 4.0 mm; nearest critical structure: incisive canal. Region 14: bone height ≈ 17.4 mm; implant space ≈ 14.3 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 17.7 mm; implant space ≈ 8.8 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 17.3 mm; implant space ≈ 9.8 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 20.5 mm; implant space ≈ 17.8 mm; nearest critical structure: incisive canal. Region 38: bone height ≈ 6.6 mm; implant space ≈ 5.0 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 21.1 mm; implant space ≈ 16.4 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 16.6 mm; implant space ≈ 10.4 mm; nearest critical structure: mandibular canal. Region 28: bone height ≈ 20.7 mm; implant space ≈ 18.8 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Peri-implant bone loss at 22 within the coronal third, suggestive of peri-implantitis.
|
|
case_0071
|
Planning for implant planning evaluation. Brief history/status: Duloxetine, Duroferon, Losartan, Atorvastatin, Amlodipine. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.
|
Review of CBCT volume dated 231110. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 21.1 mm; implant space ≈ 14.2 mm; nearest critical structure: nasal floor. Region 14: bone height ≈ 4.8 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 13.3 mm; implant space ≈ 6.8 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 19.5 mm; implant space ≈ 13.6 mm; nearest critical structure: mental foramen. Region 34: bone height ≈ 16.2 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 11.3 mm; implant space ≈ 2.3 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 21.0 mm; implant space ≈ 13.4 mm; nearest critical structure: nasal floor. Region 28: bone height ≈ 6.2 mm; implant space ≈ 0.8 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 8.0 mm; implant space ≈ 6.1 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 16.2 mm; implant space ≈ 11.1 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination.
|
|
case_0072
|
Planning for persistent pain on mastication. Brief history/status: Calcichew-D3, Amlodipine, Bufomix Easyhaler, Levaxin, Losartan, Trulicity, Metoprolol, Duroferon, Atorvastatin. Desired treatment: Please report bone height and available implant space for regions 35–45 and 17–27.
|
Review of CBCT volume dated 211109. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 18.3 mm; implant space ≈ 14.4 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 5.2 mm; implant space ≈ 1.7 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 12.4 mm; implant space ≈ 10.3 mm; nearest critical structure: mental foramen. Region 31: bone height ≈ 6.1 mm; implant space ≈ 1.3 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 12.8 mm; implant space ≈ 6.6 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 12.2 mm; implant space ≈ 9.1 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 21.0 mm; implant space ≈ 12.6 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 5.3 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 7.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 16.4 mm; implant space ≈ 9.8 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 11, likely radicular cyst.
|
|
case_0073
|
Planning for persistent pain on mastication. Brief history/status: Calcichew-D3, Trulicity, Bufomix Easyhaler, Bricanyl, Esomeprazole, Duroferon. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.
|
Review of CBCT volume dated 230901. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 5.1 mm; implant space ≈ 2.4 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 21.3 mm; implant space ≈ 15.8 mm; nearest critical structure: anterior loop. Region 37: bone height ≈ 15.4 mm; implant space ≈ 6.4 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 13.1 mm; implant space ≈ 8.2 mm; nearest critical structure: mental foramen. Region 16: bone height ≈ 11.6 mm; implant space ≈ 8.5 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 16.1 mm; implant space ≈ 7.8 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 20.8 mm; implant space ≈ 17.2 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 14.5 mm; implant space ≈ 8.9 mm; nearest critical structure: mandibular canal. Region 31: bone height ≈ 15.8 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.7 mm; implant space ≈ 2.1 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0074
|
Planning for implant site evaluation. Brief history/status: Levaxin, Calcichew-D3, Betolvex, Duloxetine, Duroferon, Bricanyl, Trulicity, Metoprolol, Atorvastatin. Desired treatment: Report any signs of peri-implantitis and root resorption in 15–25.
|
Review of CBCT volume dated 220908. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 45: bone height ≈ 18.8 mm; implant space ≈ 13.8 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 17.4 mm; implant space ≈ 15.1 mm; nearest critical structure: anterior loop. Region 18: bone height ≈ 5.0 mm; implant space ≈ 2.0 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 7.6 mm; implant space ≈ 1.1 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 16.3 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 16: bone height ≈ 9.6 mm; implant space ≈ 7.1 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 9.5 mm; implant space ≈ 4.1 mm; nearest critical structure: mandibular canal. Region 47: bone height ≈ 18.2 mm; implant space ≈ 9.4 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 19.3 mm; implant space ≈ 12.4 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 5.1 mm; implant space ≈ 3.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 45; lamina dura loss noted. Secondary small radiolucency adjacent to 28. Impression: Vertical root fracture suspected at 27; recommend clinical correlation.
|
|
case_0075
|
Planning for follow-up after extraction. Brief history/status: Betolvex, Amlodipine, Atorvastatin, Bricanyl, Metoprolol, Insulin glargine, Esomeprazole, Duloxetine, Trulicity. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 17–27.
|
Review of CBCT volume dated 251117. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 45: bone height ≈ 21.7 mm; implant space ≈ 14.9 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 6.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 19.5 mm; implant space ≈ 16.0 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 6.9 mm; implant space ≈ 4.4 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 15.9 mm; implant space ≈ 9.8 mm; nearest critical structure: sinus floor. Region 15: bone height ≈ 21.4 mm; implant space ≈ 16.5 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 4.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 20.1 mm; implant space ≈ 17.3 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 16.5 mm; implant space ≈ 10.0 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0076
|
Planning for full-arch restoration. Brief history/status: Amlodipine, Betolvex, Levaxin, Bufomix Easyhaler, Losartan, Duloxetine, Calcichew-D3, Metoprolol. Desired treatment: Provide measurements relevant to guided surgery stent planning for 37–47 and 36–46.
|
Review of CBCT volume dated 210810. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 32: bone height ≈ 4.2 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 6.5 mm; implant space ≈ 3.5 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 17.7 mm; implant space ≈ 10.6 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 9.3 mm; implant space ≈ 3.7 mm; nearest critical structure: incisive canal. Region 47: bone height ≈ 19.6 mm; implant space ≈ 16.2 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 10.8 mm; implant space ≈ 7.1 mm; nearest critical structure: mental foramen. Region 18: bone height ≈ 13.2 mm; implant space ≈ 6.2 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 11.2 mm; implant space ≈ 5.2 mm; nearest critical structure: mandibular canal. Region 16: bone height ≈ 16.3 mm; implant space ≈ 10.6 mm; nearest critical structure: incisive canal. Region 24: bone height ≈ 12.5 mm; implant space ≈ 9.9 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 34; lamina dura loss noted. Secondary small radiolucency adjacent to 43. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0077
|
Planning for sinus-related complaints. Brief history/status: Duloxetine, Metoprolol, Duroferon, Amlodipine, Levaxin, Betolvex, Losartan, Bufomix Easyhaler. Desired treatment: Report any signs of peri-implantitis and root resorption in 16–26.
|
Review of CBCT volume dated 220828. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 33: bone height ≈ 15.5 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 19.5 mm; implant space ≈ 10.9 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 18.8 mm; implant space ≈ 16.1 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 15.5 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 12.0 mm; implant space ≈ 6.8 mm; nearest critical structure: nasal floor. Region 12: bone height ≈ 7.4 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 20.1 mm; implant space ≈ 15.6 mm; nearest critical structure: mandibular canal. Region 11: bone height ≈ 21.3 mm; implant space ≈ 13.8 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 8.6 mm; implant space ≈ 5.8 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 21.1 mm; implant space ≈ 17.2 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0078
|
Planning for persistent pain on mastication. Brief history/status: Esomeprazole, Losartan, Amlodipine, Trulicity, Metoprolol, Insulin glargine, Duloxetine, Bricanyl, Betolvex. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 35–45.
|
Review of CBCT volume dated 211102. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 26: bone height ≈ 21.9 mm; implant space ≈ 14.9 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 16.8 mm; implant space ≈ 11.7 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 19.1 mm; implant space ≈ 11.7 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 18.9 mm; implant space ≈ 15.0 mm; nearest critical structure: sinus floor. Region 11: bone height ≈ 21.5 mm; implant space ≈ 16.9 mm; nearest critical structure: nasal floor. Region 36: bone height ≈ 21.6 mm; implant space ≈ 15.6 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 21.1 mm; implant space ≈ 18.1 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 4.6 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 20.0 mm; implant space ≈ 16.3 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 19.2 mm; implant space ≈ 10.7 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 27; recommend clinical correlation.
|
|
case_0079
|
Planning for pre-orthodontic assessment. Brief history/status: Duroferon, Bufomix Easyhaler, Amlodipine, Bricanyl, Metoprolol, Atorvastatin. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 36–46.
|
Review of CBCT volume dated 240602. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 27: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 26: bone height ≈ 13.4 mm; implant space ≈ 6.9 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 13.1 mm; implant space ≈ 5.7 mm; nearest critical structure: mandibular canal. Region 25: bone height ≈ 18.9 mm; implant space ≈ 14.0 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.3 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 11.5 mm; implant space ≈ 6.8 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 11.7 mm; implant space ≈ 5.9 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 8.1 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 21.5 mm; implant space ≈ 19.6 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 13.8 mm; implant space ≈ 11.7 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 38; lamina dura loss noted. Secondary small radiolucency adjacent to 31. Impression: Findings consistent with chronic apical periodontitis at 46 and 42.
|
|
case_0080
|
Planning for assessment for guided surgery. Brief history/status: Amlodipine, Levaxin, Betolvex, Duroferon, Metoprolol, Atorvastatin, Duloxetine, Bricanyl. Desired treatment: Report any signs of peri-implantitis and root resorption in 36–46.
|
Review of CBCT volume dated 250411. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 25: bone height ≈ 10.9 mm; implant space ≈ 3.2 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 16.5 mm; implant space ≈ 13.1 mm; nearest critical structure: anterior loop. Region 42: bone height ≈ 8.9 mm; implant space ≈ 6.6 mm; nearest critical structure: mandibular canal. Region 43: bone height ≈ 20.7 mm; implant space ≈ 15.3 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 6.4 mm; implant space ≈ 1.4 mm; nearest critical structure: incisive canal. Region 23: bone height ≈ 20.4 mm; implant space ≈ 14.8 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 18.3 mm; implant space ≈ 13.7 mm; nearest critical structure: incisive canal. Region 34: bone height ≈ 18.1 mm; implant space ≈ 13.3 mm; nearest critical structure: mental foramen. Region 37: bone height ≈ 18.1 mm; implant space ≈ 14.0 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 10.6 mm; implant space ≈ 4.9 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 35; lamina dura loss noted. Secondary small radiolucency adjacent to 44. Impression: Peri-implant bone loss at 42 within the coronal third, suggestive of peri-implantitis.
|
|
case_0081
|
Planning for persistent pain on mastication. Brief history/status: Levaxin, Betolvex, Amlodipine, Losartan, Trulicity. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 15–25.
|
Review of CBCT volume dated 211228. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 28: bone height ≈ 21.0 mm; implant space ≈ 15.5 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 7.3 mm; implant space ≈ 2.8 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 9.5 mm; implant space ≈ 5.0 mm; nearest critical structure: nasal floor. Region 43: bone height ≈ 18.6 mm; implant space ≈ 14.3 mm; nearest critical structure: mental foramen. Region 13: bone height ≈ 19.2 mm; implant space ≈ 15.9 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 20.3 mm; implant space ≈ 12.4 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 20.9 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 12.8 mm; implant space ≈ 6.5 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 5.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 19.7 mm; implant space ≈ 13.0 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Vertical root fracture suspected at 17; recommend clinical correlation.
|
|
case_0082
|
Planning for pre-surgical bone mapping. Brief history/status: Duloxetine, Trulicity, Calcichew-D3, Atorvastatin, Levaxin. Desired treatment: Measure crest-to-canal distances mandibularly in 17–27, and implant feasibility maxillary 15–25.
|
Review of CBCT volume dated 220904. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 22: bone height ≈ 17.9 mm; implant space ≈ 14.1 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.8 mm; implant space ≈ 2.4 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 13.7 mm; implant space ≈ 12.0 mm; nearest critical structure: mandibular canal. Region 34: bone height ≈ 17.5 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 19.6 mm; implant space ≈ 14.6 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 8.2 mm; implant space ≈ 3.1 mm; nearest critical structure: mandibular canal. Region 13: bone height ≈ 13.7 mm; implant space ≈ 11.9 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 8.0 mm; implant space ≈ 5.9 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 9.8 mm; implant space ≈ 8.1 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 13.2 mm; implant space ≈ 8.4 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0083
|
Planning for pre-surgical bone mapping. Brief history/status: Amlodipine, Esomeprazole, Bricanyl, Duloxetine, Bufomix Easyhaler. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.
|
Review of CBCT volume dated 250925. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 41: bone height ≈ 6.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 34: bone height ≈ 13.2 mm; implant space ≈ 4.9 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 10.9 mm; implant space ≈ 6.9 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 6.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 18.4 mm; implant space ≈ 14.8 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 13.1 mm; implant space ≈ 11.3 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 13.4 mm; implant space ≈ 8.9 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 18.3 mm; implant space ≈ 13.1 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 8.6 mm; implant space ≈ 0.6 mm; nearest critical structure: mental foramen. Region 48: bone height ≈ 21.3 mm; implant space ≈ 13.4 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination.
|
|
case_0084
|
Planning for sinus-related complaints. Brief history/status: Atorvastatin, Levaxin, Amlodipine, Metoprolol, Esomeprazole, Betolvex. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 17–27.
|
Review of CBCT volume dated 250605. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 16: bone height ≈ 9.8 mm; implant space ≈ 7.7 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 17: bone height ≈ 17.8 mm; implant space ≈ 14.1 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 8.1 mm; implant space ≈ 4.2 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 17.8 mm; implant space ≈ 13.5 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 21.1 mm; implant space ≈ 18.8 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 6.0 mm; implant space ≈ 0.9 mm; nearest critical structure: anterior loop. Region 43: bone height ≈ 17.7 mm; implant space ≈ 11.0 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 8.3 mm; implant space ≈ 0.3 mm; nearest critical structure: nasal floor. Region 24: bone height ≈ 13.9 mm; implant space ≈ 11.7 mm; nearest critical structure: nasal floor. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0085
|
Planning for pre-surgical bone mapping. Brief history/status: Esomeprazole, Atorvastatin, Levaxin, Trulicity, Insulin glargine, Metoprolol, Calcichew-D3. Desired treatment: Quantify vertical bone loss around implants in 15–25 and assess anterior maxillary density.
|
Review of CBCT volume dated 201206. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 21: bone height ≈ 8.9 mm; implant space ≈ 6.2 mm; nearest critical structure: incisive canal. Region 12: bone height ≈ 7.9 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 8.0 mm; implant space ≈ 5.6 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 21.2 mm; implant space ≈ 15.5 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 37: bone height ≈ 15.7 mm; implant space ≈ 10.8 mm; nearest critical structure: mental foramen. Region 42: bone height ≈ 14.6 mm; implant space ≈ 9.3 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 12.1 mm; implant space ≈ 3.9 mm; nearest critical structure: mandibular canal. Region 41: bone height ≈ 7.1 mm; implant space ≈ 3.8 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 11.4 mm; implant space ≈ 7.1 mm; nearest critical structure: sinus floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 14; lamina dura loss noted. Secondary small radiolucency adjacent to 46. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination.
|
|
case_0086
|
Planning for pre-surgical bone mapping. Brief history/status: Calcichew-D3, Trulicity, Atorvastatin, Metoprolol, Amlodipine, Losartan, Bufomix Easyhaler, Betolvex. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 37–47.
|
Review of CBCT volume dated 220604. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 35: bone height ≈ 4.3 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 27: bone height ≈ 15.0 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 13: bone height ≈ 13.1 mm; implant space ≈ 9.6 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 10.9 mm; implant space ≈ 5.0 mm; nearest critical structure: incisive canal. Region 48: bone height ≈ 13.8 mm; implant space ≈ 5.3 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 17.5 mm; implant space ≈ 13.4 mm; nearest critical structure: sinus floor. Region 36: bone height ≈ 21.0 mm; implant space ≈ 13.8 mm; nearest critical structure: mental foramen. Region 43: bone height ≈ 16.5 mm; implant space ≈ 10.0 mm; nearest critical structure: mandibular canal. Region 33: bone height ≈ 13.2 mm; implant space ≈ 7.6 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 19.2 mm; implant space ≈ 15.4 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 16; lamina dura loss noted. Secondary small radiolucency adjacent to 42. Impression: Vertical root fracture suspected at 11; recommend clinical correlation.
|
|
case_0087
|
Planning for implant site evaluation. Brief history/status: Calcichew-D3, Esomeprazole, Bricanyl, Metoprolol, Betolvex. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 17–27.
|
Review of CBCT volume dated 201221. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 19.2 mm; implant space ≈ 10.9 mm; nearest critical structure: sinus floor. Region 34: bone height ≈ 5.9 mm; implant space ≈ 4.1 mm; nearest critical structure: mandibular canal. Region 14: bone height ≈ 12.9 mm; implant space ≈ 8.6 mm; nearest critical structure: sinus floor. Region 17: bone height ≈ 13.7 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 16: bone height ≈ 13.5 mm; implant space ≈ 9.5 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 15.7 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 12: bone height ≈ 20.1 mm; implant space ≈ 12.4 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 6.9 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 26: bone height ≈ 20.8 mm; implant space ≈ 19.2 mm; nearest critical structure: incisive canal. Region 35: bone height ≈ 13.1 mm; implant space ≈ 11.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0088
|
Planning for delayed healing post endodontic therapy. Brief history/status: Esomeprazole, Metoprolol, Atorvastatin, Insulin glargine, Amlodipine. Desired treatment: Measure crest-to-canal distances mandibularly in 15–25, and implant feasibility maxillary 36–46.
|
Review of CBCT volume dated 250610. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 37: bone height ≈ 12.8 mm; implant space ≈ 7.1 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 21.7 mm; implant space ≈ 14.0 mm; nearest critical structure: mental foramen. Region 25: bone height ≈ 12.2 mm; implant space ≈ 5.9 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 12.4 mm; implant space ≈ 7.1 mm; nearest critical structure: sinus floor. Region 18: bone height ≈ 9.7 mm; implant space ≈ 5.8 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 15.0 mm; implant space ≈ 8.9 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 20.2 mm; implant space ≈ 17.2 mm; nearest critical structure: sinus floor. Region 43: bone height ≈ 7.9 mm; implant space ≈ 5.2 mm; nearest critical structure: anterior loop. Region 41: bone height ≈ 4.3 mm; implant space ≈ 0.5 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 10.5 mm; implant space ≈ 8.2 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 11; lamina dura loss noted. Secondary small radiolucency adjacent to 21. Impression: Mild to moderate mucosal thickening bilaterally in maxillary sinuses.
|
|
case_0089
|
Planning for persistent pain on mastication. Brief history/status: Insulin glargine, Esomeprazole, Betolvex, Amlodipine, Duloxetine, Metoprolol, Levaxin, Atorvastatin, Losartan. Desired treatment: Please report bone height and available implant space for regions 36–46 and 37–47.
|
Review of CBCT volume dated 220128. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 14: bone height ≈ 14.5 mm; implant space ≈ 8.2 mm; nearest critical structure: nasal floor. Region 15: bone height ≈ 16.5 mm; implant space ≈ 8.2 mm; nearest critical structure: sinus floor. Region 12: bone height ≈ 8.1 mm; implant space ≈ 0.4 mm; nearest critical structure: nasal floor. Region 18: bone height ≈ 14.1 mm; implant space ≈ 12.5 mm; nearest critical structure: nasal floor. Region 22: bone height ≈ 9.4 mm; implant space ≈ 5.4 mm; nearest critical structure: nasal floor. Region 44: bone height ≈ 8.4 mm; implant space ≈ 0.2 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 18.6 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 47: bone height ≈ 9.6 mm; implant space ≈ 4.5 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 14.8 mm; implant space ≈ 8.8 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.3 mm; implant space ≈ 8.2 mm; nearest critical structure: anterior loop. Impression: Peri-implant bone loss at 43 within the coronal third, suggestive of peri-implantitis.
|
|
case_0090
|
Planning for delayed healing post endodontic therapy. Brief history/status: Duroferon, Betolvex, Duloxetine, Amlodipine, Levaxin, Losartan, Metoprolol. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 16–26.
|
Review of CBCT volume dated 210715. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 18: bone height ≈ 17.3 mm; implant space ≈ 12.6 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 19.7 mm; implant space ≈ 14.1 mm; nearest critical structure: anterior loop. Region 12: bone height ≈ 16.1 mm; implant space ≈ 9.4 mm; nearest critical structure: sinus floor. Region 27: bone height ≈ 4.9 mm; implant space ≈ 1.7 mm; nearest critical structure: incisive canal. Region 22: bone height ≈ 11.6 mm; implant space ≈ 7.8 mm; nearest critical structure: nasal floor. Region 26: bone height ≈ 13.3 mm; implant space ≈ 11.2 mm; nearest critical structure: nasal floor. Region 34: bone height ≈ 7.0 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 46: bone height ≈ 11.7 mm; implant space ≈ 3.5 mm; nearest critical structure: mental foramen. Region 45: bone height ≈ 10.8 mm; implant space ≈ 5.4 mm; nearest critical structure: mental foramen. Region 33: bone height ≈ 8.0 mm; implant space ≈ 1.4 mm; nearest critical structure: mental foramen. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Cyst-like well-defined radiolucency near 48, likely radicular cyst.
|
|
case_0091
|
Planning for delayed healing post endodontic therapy. Brief history/status: Amlodipine, Levaxin, Duroferon, Bricanyl, Duloxetine, Esomeprazole, Trulicity, Bufomix Easyhaler. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 35–45.
|
Review of CBCT volume dated 201104. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 32: bone height ≈ 5.6 mm; implant space ≈ 3.9 mm; nearest critical structure: anterior loop. Region 45: bone height ≈ 11.4 mm; implant space ≈ 8.9 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 14.0 mm; implant space ≈ 10.4 mm; nearest critical structure: nasal floor. Region 48: bone height ≈ 15.7 mm; implant space ≈ 8.6 mm; nearest critical structure: anterior loop. Region 14: bone height ≈ 11.6 mm; implant space ≈ 8.7 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 9.5 mm; implant space ≈ 3.5 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 7.7 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 16: bone height ≈ 14.0 mm; implant space ≈ 12.0 mm; nearest critical structure: nasal floor. Region 17: bone height ≈ 17.2 mm; implant space ≈ 11.3 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 12.0 mm; implant space ≈ 8.5 mm; nearest critical structure: mandibular canal. Impression: Peri-implant bone loss at 45 within the coronal third, suggestive of peri-implantitis.
|
|
case_0092
|
Planning for persistent pain on mastication. Brief history/status: Betolvex, Atorvastatin, Metoprolol, Duroferon, Insulin glargine, Calcichew-D3, Duloxetine, Bricanyl. Desired treatment: Measure crest-to-canal distances mandibularly in 35–45, and implant feasibility maxillary 35–45.
|
Review of CBCT volume dated 221011. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 25: bone height ≈ 8.2 mm; implant space ≈ 2.2 mm; nearest critical structure: sinus floor. Region 13: bone height ≈ 11.3 mm; implant space ≈ 3.6 mm; nearest critical structure: sinus floor. Region 28: bone height ≈ 8.9 mm; implant space ≈ 2.8 mm; nearest critical structure: sinus floor. Region 26: bone height ≈ 9.0 mm; implant space ≈ 3.7 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 15.1 mm; implant space ≈ 6.6 mm; nearest critical structure: incisive canal. Region 37: bone height ≈ 7.0 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 47: bone height ≈ 13.8 mm; implant space ≈ 6.3 mm; nearest critical structure: anterior loop. Region 24: bone height ≈ 17.5 mm; implant space ≈ 9.4 mm; nearest critical structure: nasal floor. Region 45: bone height ≈ 9.6 mm; implant space ≈ 2.5 mm; nearest critical structure: anterior loop. Region 22: bone height ≈ 13.9 mm; implant space ≈ 10.8 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 21; lamina dura loss noted. Secondary small radiolucency adjacent to 16. Impression: Cyst-like well-defined radiolucency near 16, likely radicular cyst.
|
|
case_0093
|
Planning for full-arch restoration. Brief history/status: Esomeprazole, Losartan, Calcichew-D3, Bufomix Easyhaler, Betolvex, Bricanyl. Desired treatment: Assess presence of periapical lesions and proximity to anatomical structures across 36–46.
|
Review of CBCT volume dated 220820. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 44: bone height ≈ 10.0 mm; implant space ≈ 3.7 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 6.1 mm; implant space ≈ 4.1 mm; nearest critical structure: anterior loop. Region 38: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: mental foramen. Region 35: bone height ≈ 13.9 mm; implant space ≈ 10.7 mm; nearest critical structure: anterior loop. Region 17: bone height ≈ 14.9 mm; implant space ≈ 8.1 mm; nearest critical structure: incisive canal. Region 27: bone height ≈ 12.7 mm; implant space ≈ 4.1 mm; nearest critical structure: sinus floor. Region 23: bone height ≈ 11.2 mm; implant space ≈ 7.6 mm; nearest critical structure: nasal floor. Region 33: bone height ≈ 11.0 mm; implant space ≈ 4.4 mm; nearest critical structure: mandibular canal. Region 24: bone height ≈ 15.1 mm; implant space ≈ 8.3 mm; nearest critical structure: sinus floor. Region 42: bone height ≈ 15.0 mm; implant space ≈ 9.5 mm; nearest critical structure: mandibular canal. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 21 and 25.
|
|
case_0094
|
Planning for implant site evaluation. Brief history/status: Atorvastatin, Duloxetine, Losartan, Bricanyl, Calcichew-D3, Trulicity. Desired treatment: Provide measurements relevant to guided surgery stent planning for 17–27 and 15–25.
|
Review of CBCT volume dated 230510. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 34: bone height ≈ 15.1 mm; implant space ≈ 8.8 mm; nearest critical structure: anterior loop. Region 44: bone height ≈ 16.7 mm; implant space ≈ 14.2 mm; nearest critical structure: mandibular canal. Region 45: bone height ≈ 13.5 mm; implant space ≈ 10.0 mm; nearest critical structure: anterior loop. Region 46: bone height ≈ 6.6 mm; implant space ≈ 1.1 mm; nearest critical structure: anterior loop. Region 47: bone height ≈ 11.4 mm; implant space ≈ 8.7 mm; nearest critical structure: mental foramen. Region 21: bone height ≈ 8.2 mm; implant space ≈ 2.6 mm; nearest critical structure: sinus floor. Region 35: bone height ≈ 6.3 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 14.3 mm; implant space ≈ 10.8 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 15.1 mm; implant space ≈ 11.8 mm; nearest critical structure: sinus floor. Region 14: bone height ≈ 7.9 mm; implant space ≈ 3.5 mm; nearest critical structure: incisive canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 36; lamina dura loss noted. Secondary small radiolucency adjacent to 43. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Impaction of third molar in quadrant 2 with mesioangular inclination.
|
|
case_0095
|
Planning for implant site evaluation. Brief history/status: Metoprolol, Bufomix Easyhaler, Bricanyl, Betolvex, Duroferon, Duloxetine, Amlodipine, Trulicity, Insulin glargine. Desired treatment: Please report bone height and available implant space for regions 15–25 and 35–45.
|
Review of CBCT volume dated 251114. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 24: bone height ≈ 10.6 mm; implant space ≈ 3.6 mm; nearest critical structure: incisive canal. Region 18: bone height ≈ 10.8 mm; implant space ≈ 4.5 mm; nearest critical structure: incisive canal. Region 33: bone height ≈ 4.5 mm; implant space ≈ 2.1 mm; nearest critical structure: anterior loop. Region 48: bone height ≈ 13.6 mm; implant space ≈ 7.9 mm; nearest critical structure: anterior loop. Region 11: bone height ≈ 21.2 mm; implant space ≈ 15.4 mm; nearest critical structure: nasal floor. Region 41: bone height ≈ 8.3 mm; implant space ≈ 5.9 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 6.2 mm; implant space ≈ 1.8 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 21.2 mm; implant space ≈ 13.7 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 5.2 mm; implant space ≈ 1.0 mm; nearest critical structure: nasal floor. Region 35: bone height ≈ 21.1 mm; implant space ≈ 12.2 mm; nearest critical structure: mandibular canal. Impression: Impaction of third molar in quadrant 1 with mesioangular inclination.
|
|
case_0096
|
Planning for delayed healing post endodontic therapy. Brief history/status: Bufomix Easyhaler, Bricanyl, Metoprolol, Levaxin, Amlodipine, Esomeprazole, Atorvastatin. Desired treatment: Quantify vertical bone loss around implants in 16–26 and assess anterior maxillary density.
|
Review of CBCT volume dated 220604. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 35: bone height ≈ 7.6 mm; implant space ≈ 1.0 mm; nearest critical structure: mental foramen. Region 46: bone height ≈ 18.4 mm; implant space ≈ 16.3 mm; nearest critical structure: anterior loop. Region 33: bone height ≈ 10.3 mm; implant space ≈ 6.7 mm; nearest critical structure: mental foramen. Region 38: bone height ≈ 21.0 mm; implant space ≈ 15.4 mm; nearest critical structure: mental foramen. Region 36: bone height ≈ 8.4 mm; implant space ≈ 1.7 mm; nearest critical structure: anterior loop. Region 13: bone height ≈ 8.5 mm; implant space ≈ 2.1 mm; nearest critical structure: sinus floor. Region 21: bone height ≈ 8.1 mm; implant space ≈ 4.8 mm; nearest critical structure: sinus floor. Region 16: bone height ≈ 14.1 mm; implant space ≈ 8.1 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 9.7 mm; implant space ≈ 2.3 mm; nearest critical structure: mandibular canal. Region 44: bone height ≈ 15.6 mm; implant space ≈ 13.3 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 18; lamina dura loss noted. Secondary small radiolucency adjacent to 45. Impression: Bone quantity borderline in posterior maxilla; sinus augmentation may be indicated.
|
|
case_0097
|
Planning for pre-surgical bone mapping. Brief history/status: Insulin glargine, Trulicity, Betolvex, Metoprolol, Esomeprazole, Losartan. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 36–46.
|
Review of CBCT volume dated 240220. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 21: bone height ≈ 11.0 mm; implant space ≈ 8.5 mm; nearest critical structure: nasal floor. Region 32: bone height ≈ 5.6 mm; implant space ≈ 0.0 mm; nearest critical structure: mandibular canal. Region 17: bone height ≈ 6.8 mm; implant space ≈ 0.9 mm; nearest critical structure: sinus floor. Region 46: bone height ≈ 14.2 mm; implant space ≈ 8.7 mm; nearest critical structure: anterior loop. Region 15: bone height ≈ 19.8 mm; implant space ≈ 15.8 mm; nearest critical structure: incisive canal. Region 43: bone height ≈ 4.1 mm; implant space ≈ 2.3 mm; nearest critical structure: mental foramen. Region 14: bone height ≈ 11.5 mm; implant space ≈ 6.0 mm; nearest critical structure: nasal floor. Region 23: bone height ≈ 10.5 mm; implant space ≈ 6.9 mm; nearest critical structure: incisive canal. Region 25: bone height ≈ 8.3 mm; implant space ≈ 4.5 mm; nearest critical structure: nasal floor. Region 38: bone height ≈ 4.4 mm; implant space ≈ 0.0 mm; nearest critical structure: anterior loop. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 21; lamina dura loss noted. Secondary small radiolucency adjacent to 17. Streak artifacts from metallic restorations locally reduce interpretability. Impression: Findings consistent with chronic apical periodontitis at 26 and 21.
|
|
case_0098
|
Planning for pre-surgical bone mapping. Brief history/status: Trulicity, Betolvex, Esomeprazole, Metoprolol, Calcichew-D3, Amlodipine, Atorvastatin. Desired treatment: Provide measurements relevant to guided surgery stent planning for 16–26 and 37–47.
|
Review of CBCT volume dated 240621. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 43: bone height ≈ 11.8 mm; implant space ≈ 8.2 mm; nearest critical structure: mandibular canal. Region 37: bone height ≈ 16.6 mm; implant space ≈ 11.0 mm; nearest critical structure: mandibular canal. Region 48: bone height ≈ 17.9 mm; implant space ≈ 12.3 mm; nearest critical structure: mental foramen. Region 28: bone height ≈ 10.7 mm; implant space ≈ 4.7 mm; nearest critical structure: sinus floor. Region 47: bone height ≈ 18.8 mm; implant space ≈ 12.8 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 10.0 mm; implant space ≈ 6.6 mm; nearest critical structure: mental foramen. Region 24: bone height ≈ 4.1 mm; implant space ≈ 0.0 mm; nearest critical structure: incisive canal. Region 17: bone height ≈ 5.7 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 42: bone height ≈ 16.9 mm; implant space ≈ 9.6 mm; nearest critical structure: mental foramen. Region 26: bone height ≈ 18.9 mm; implant space ≈ 14.4 mm; nearest critical structure: incisive canal. Periapical radiolucency present near 46; lamina dura loss noted. Secondary small radiolucency adjacent to 43. Impression: Peri-implant bone loss at 44 within the coronal third, suggestive of peri-implantitis.
|
|
case_0099
|
Planning for pre-surgical bone mapping. Brief history/status: Duloxetine, Levaxin, Betolvex, Amlodipine, Bricanyl, Insulin glargine, Metoprolol, Trulicity, Atorvastatin. Desired treatment: Quantify vertical bone loss around implants in 35–45 and assess anterior maxillary density.
|
Review of CBCT volume dated 241015. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 33: bone height ≈ 12.5 mm; implant space ≈ 8.8 mm; nearest critical structure: mandibular canal. Region 36: bone height ≈ 17.2 mm; implant space ≈ 9.3 mm; nearest critical structure: mandibular canal. Region 35: bone height ≈ 9.0 mm; implant space ≈ 0.9 mm; nearest critical structure: anterior loop. Region 23: bone height ≈ 16.6 mm; implant space ≈ 7.6 mm; nearest critical structure: sinus floor. Region 44: bone height ≈ 6.7 mm; implant space ≈ 2.6 mm; nearest critical structure: mandibular canal. Region 26: bone height ≈ 7.5 mm; implant space ≈ 4.6 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 9.2 mm; implant space ≈ 0.3 mm; nearest critical structure: anterior loop. Region 21: bone height ≈ 8.5 mm; implant space ≈ 6.7 mm; nearest critical structure: nasal floor. Region 37: bone height ≈ 6.2 mm; implant space ≈ 3.8 mm; nearest critical structure: anterior loop. Region 27: bone height ≈ 19.6 mm; implant space ≈ 16.5 mm; nearest critical structure: nasal floor. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Periapical radiolucency present near 44; lamina dura loss noted. Secondary small radiolucency adjacent to 27. Impression: No acute pathology identified; anatomy within expected limits for planned procedures.
|
|
case_0100
|
Planning for pre-surgical bone mapping. Brief history/status: Atorvastatin, Betolvex, Levaxin, Losartan, Bricanyl, Insulin glargine, Duloxetine. Desired treatment: Measure crest-to-canal distances mandibularly in 17–27, and implant feasibility maxillary 15–25.
|
Review of CBCT volume dated 251027. Bone quality ranges from ordinary to reduced in posterior segments. Implant space is referenced from a 5 mm minimal bone width threshold. Region 26: bone height ≈ 12.3 mm; implant space ≈ 6.0 mm; nearest critical structure: sinus floor. Region 32: bone height ≈ 13.2 mm; implant space ≈ 9.2 mm; nearest critical structure: mental foramen. Region 23: bone height ≈ 18.0 mm; implant space ≈ 9.2 mm; nearest critical structure: incisive canal. Region 15: bone height ≈ 13.1 mm; implant space ≈ 9.3 mm; nearest critical structure: nasal floor. Region 46: bone height ≈ 11.8 mm; implant space ≈ 5.3 mm; nearest critical structure: mandibular canal. Region 18: bone height ≈ 18.5 mm; implant space ≈ 14.9 mm; nearest critical structure: sinus floor. Region 24: bone height ≈ 5.2 mm; implant space ≈ 0.0 mm; nearest critical structure: nasal floor. Region 25: bone height ≈ 4.9 mm; implant space ≈ 0.0 mm; nearest critical structure: sinus floor. Region 41: bone height ≈ 9.7 mm; implant space ≈ 1.6 mm; nearest critical structure: mandibular canal. Region 38: bone height ≈ 11.7 mm; implant space ≈ 6.1 mm; nearest critical structure: mandibular canal. Maxillary sinuses: mucosal thickening mild to moderate bilaterally. Impression: Vertical root fracture suspected at 41; recommend clinical correlation.
|
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 11